Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 35 Quick Ratio is 5.63 as of Dec. 2025, which is 31% above its 10-year median of 4.30. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,993 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 93.38% on this metric.
Star Combo Pharma (ASX:S66) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Star Combo Pharma Quick Ratio Related Terms
Star Combo Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Star Combo Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Quick Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Star Combo Pharma's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Combo Pharma (ASX:S66) has a Quick Ratio of 5.63 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Star Combo Pharma and its competitors. This is 31% above median its historical median of 4.30. Over the past decade, Star Combo Pharma's Quick Ratio has ranged from 1.05 to 7.71. According to the industry distribution chart, Star Combo Pharma ranks #132 out of 1993 companies in the Consumer Packaged Goods industry, placing it in the top 6.6%.
Is Star Combo Pharma's Quick Ratio too high?
Star Combo Pharma's current Quick Ratio of 5.63 is 31% above median its 10-year median of 4.30. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 7.71. The Consumer Packaged Goods industry median Quick Ratio is 1.10. Star Combo Pharma's value of 5.63 is 411.8% above this industry median. Based on the distribution chart, Star Combo Pharma ranks #132 out of 1993 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Quick Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #132 out of 1993 companies for Quick Ratio. This places Star Combo Pharma in the top 7% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.10. Star Combo Pharma's value of 5.63 is 411.8% above this benchmark. Historically, Star Combo Pharma's own Quick Ratio has ranged from 1.05 to 7.71 over the past decade. While the company's 10-year median is 4.30 vs. the industry median of 1.10, Star Combo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Consumer Packaged Goods company?
The median Quick Ratio among Consumer Packaged Goods companies is 1.10, based on 1,993 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current Quick Ratio of 5.63 is 411.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median Quick Ratio is 1.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Quick Ratio is 5.63, which is 31% above median its own 10-year median of 4.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current Quick Ratio is 5.63, which is 31% above median its 10-year median of 4.30 and 411.8% above the Consumer Packaged Goods industry median of 1.10. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Quick Ratio is 5.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued.
The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Quick Ratio: 5.63 (31% above median its 10-year median of 4.30)
GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
Industry Position: 411.8% above the Consumer Packaged Goods median (#132 of 1993)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score
Get the complete analysis for ASX:S66
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
